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Abstract 
 
The increased incidence of type II diabetes has emerged as a major concern in controlled human 
immunodeficiency virus (HIV) infection. There is a general lack of data to support the best combined 
antiretroviral therapy (cART) option to treat HIV-patients with pre-diabetes and nevirapine has been 
described has a glucose-friendly antiretroviral. On the other hand, it is known that diabetes could 
influence the pharmacokinetics of several drugs. This aspect is particularly relevant for drugs with 
narrow therapeutic window, which is the case of nevirapine.  
To understand if nevirapine is a good choice for pre-diabetic HIV-patients, the effect of insulin 
resistance in NVP pharmacokinetics as well as the effect of nevirapine on insulin resistance, fasting 
glycemia and mean arterial pressure was evaluated. Moreover, nevirapine effect on thiols content, an 
endogenous antioxidant defence system, was also evaluated. To achieve the main goal four groups of 
female Wistar rat were used: a control group, a control group treated with nevirapine, an insulin 
resistant group and an insulin resistant group treated with nevirapine.  
An influence of a pre-diabetic status on nevirapine pharmacokinetic was found. Nevirapine and its 
phase I metabolites presented changes in disposition and the metabolite profile pattern was changed. 
Moreover, nevirapine, in a pre-diabetic perspective, is associated with a beneficial effect on fasting 
glycemia, while it has no effect on sensitivity to insulin or in arterial pressure. Furthermore, nevirapine 
is associated with a lower degradation of total glutathione.  
Nevirapine might be a good option for HIV-infected patients at higher risk of develop diabetes or in 
pre-diabetic condition. Moreover, while further studies are necessary to consolidate this issue, 
nevirapine might be less toxic in pre-diabetes. Although, the decreased bioavailability of nevirapine in 
pre-diabetes requires special attention, as an adjustment of nevirapine dose might be required in this 
subpopulation.     
 
Keywords: nevirapine, pre-diabetes, insulin resistance, drug toxicity, antioxidant defense 
system 
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Resumo 
 
A incidência de diabetes tipo II na infecção pelo vírus da imunodeficiência humana (VIH) tem vindo 
a aumentar. A evidência científica que justifique a melhor opção terapêutica para doentes VIH 
positivos pré-diabéticos é actualmente muito limitada. No entanto, a nevirapina tem-se destacado por 
apresentar uma influência favorável no metabolismo da glucose. Por outro lado, as alterações na 
farmacocinética dos medicamentos num contexto de diabetes estão bem documentadas. Este 
aspecto é de grande importância para um fármaco com uma janela terapêutica estreita, de que é 
exemplo a nevirapina. 
De forma a explorar a indicação da NVP para indivíduos pré-diabéticos VIH positivos, o efeito da 
insulinorresistência na farmacocinética da nevirapina, assim como o efeito da nevirapina na 
resistência à insulina, glucose em jejum e pressão arterial foi avaliado. Para atingir este objectivo, 
recorreu-se a quatro grupos constituídos por ratos Wistar fêmeas: grupo controlo, grupo controlo 
tratado com nevirapina, grupo insulinorresistente e grupo insulinorresistente tratado com nevirapina. 
A influência da pré-diabetes na farmacocinética da nevirapine foi comprovada manifestando-se 
como uma variação na disposição da nevirapina e seus metabolitos de fase I, assim como um 
diferente perfil de metabolitos. Para além disso, o tratamento com nevirapina parece estar associado 
a uma melhoria dos níveis de glucose em jejum e a uma menor degradação do glutatião. Estes novos 
dados sugerem que a nevirapina possa ser eleita como uma boa opção para doentes VIH positivos 
com elevado risco para desenvolver diabetes ou pré-diabetes. Por outro lado, e apesar da 
necessidade de mais estudos para consolidar esta hipótese, a nevirapine poderá ser menos tóxica 
num contexto de pré-diabetes. Por último é relevante salientar que a diminuição da biodisponibilidade 
da nevirapina na pré-diabetes requer uma especial atenção, pela possível necessidade de um ajuste 
de dose nesta sub-população. 
 
Palavras-chave: nevirapine, pré-diabetes, resistência à insulina, toxicidade medicamentosa, 
sistema de defesa antioxidante.  
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1.1 Human immunodeficiency virus infection and the combined 
antiretroviral therapy 
 
The numbers of HIV-infection are tremendous: from 2001 to 2011 this figure increased by 5 million 
people, reaching 34 million of infected individuals, which correspond to 0.8% of adult population 
worldwide. In this scary scenario, the health promotion regarding this infection and the availability of 
combined antiretroviral therapy (cART) in middle 90’s have totally revolutionized the prognostic of this 
infection, which nowadays is considered a chronic condition in properly medicated patients. The good 
numbers reflect the increased decline in HIV-associated deaths of approximately 600 thousands from 
2005 to 2011. Moreover, during the year 2011, the number of persons which had benefit from anti-HIV 
treatment, increased by 1.6 million people  (World Health Organization, 2013). Currently there are 
more than 20 antiretroviral drugs available, distributed into five major classes which are classified 
according their mechanisms of action (Figure 1.1). 
The choice of cART for a particular patient and the optimal times for its start should be in 
agreement with several elements, such as clinical manifestations, the number of lymphocytes CD4 
(<350 cell/mm3), the value of plasma viral load and the presence of co-morbidities. The first-line cART 
is normally composed by two nucleoside reverse transcriptase inhibitors (NRTI) combined with a third 
drug which should be preferentially a non-nucleoside reverse transcriptase inhibitor (NNRTI), namely 
efavirenz or nevirapine (Guerreiro et al., 2012). 
As, so far, the cure for HIV-infection has not been found, once a patient starts cART it must persist 
through his/her life. Moreover, despite the undoubtedly benefit of cART in patient’s life expectancy and 
quality of life, antiretrovirals are associated with several undesirable effects. Moreover, the persistent 
immune dysfunction and chronic inflammation characteristic of this infection, patient’s lifestyle risk 
factors (smoking, alcohol misuse), polymedication and higher risk for drug–drug interactions potentiate 
the increased risk of antiretroviral induced toxicity. Additionally, as patients live longer the incidence of 
aging-associated complications has been increasing in this population (Deeks and Phillips, 2009). In 
the top of the list are metabolic disorders, including insulin resistance (IR), diabetes mellitus, 
dyslipidemia and lypodystrophia (Samaras, 2012; Kalra and Agrawal, 2013). 
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Figure 1.1 - The life cycle of HIV infection and antiretroviral drug class target. In: (Smith et al., 2013)  
These classes target the following steps in the HIV life cycle: binging and fusion, reverse transcription, integration, 
transcription, assembly and finally budding. Entry inhibitors interfere with viral entry into the host cell; nucleoside 
reverse transcriptase inhibitors (NRTI) inhibit the HIV protein reverse transcriptase; non-nucleoside reverse 
transcriptase inhibitors (NNRTI) also inhibits the reverse transcriptase enzyme but in a non-competitive manner; 
protease inhibitors (PI) inhibit the protease enzyme and thus the HIV replication; integrase inhibitors (INI) interfere 
with viral integrase which is responsible for viral DNA interaction in human immune cells; maturation inhibitors 
disrupt the final step in the processing of the HIV gag protein (De Clercq, 2007; Richards and McCallister, 2008). 
 
 
1.2 Human immunodeficiency virus infection and the combined 
antiretroviral therapy and type II diabetes 
Improved methods for detection of HIV, an earlier HIV diagnosis as well as a better management of 
cART have translated this infection into lesser morbidity and mortality and a consequent longer 
lifespan. Although, in clinical practice, it has meant an increase in the chronic complications 
associated with this infection (Deeks and Phillips, 2009).  
As treatment of HIV management develops and the access to therapy improves, the incidence of 
HIV-associated diabetes is bound to grow (Paik and Kotler, 2011). The range of potential adverse 
consequences of cART is wide and includes gastro-intestinal disturbance, hepatotoxicity, pancreatitis 
and mitochondrial toxicity (Kalra et al., 2011). Thus, risk associations between HIV, its treatment, and 
diabetes have been reported in adults and children (Brown et al., 2005; Samaras et al., 2007). For 
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instance, in 130 children aged 10 years, it was observed a 13.2% prevalence of IR associated to 
cART (Beregszaszi et al., 2005). Also, in a young adult cohort of 755 HIV-infected patients with a 
mean age among 36-48 years, a prevalence rate of 4.5%, 9.4% and 11.9% of diabetes, impaired 
fasting glucose and hyperinsulinemia was respectively found (Calza et al., 2011). 
The mechanism for this is unknown but it is thought to either be due to the infectious/inflammatory 
process of HIV itself or a form of drug induced toxicity or perhaps through indirect effects. Beyond the 
conventional risk factors as family history, hypertension, male gender, certain ethnic backgrounds or 
culture aging (Kilby and Tabereaux, 1998), the individuals infected with HIV have additional factors 
that contribute to a higher risk. These factors include chronic inflammation caused by the virus, viral 
factors (viral burden, lower CD4 count and duration of viral infection) (Kilby and Tabereaux, 1998; 
Capeau et al., 2012), co-pathologies diseases (e.g., chronic hepatitis C infection (HCV)) (Mehta et al., 
2003) and factors related with antiretroviral drugs (Lewis et al., 2003; Limone et al., 2003). Despite 
there is no predominant metabolic effect for each antiretroviral class, the most undesirable metabolic 
effects have been described for protease inhibitors (PIs) (Murata et al., 2000; Noor et al., 2004; 
Stanley et al., 2009). The influence of nucleotide reverse transcriptase inhibitors (NRTIs) is 
controversial and dependent on each particular drug (Mulligan et al., 2000; Justman et al., 2003; 
Brown et al., 2005; Tien et al., 2007; De Wit et al., 2008). The NNRTI NVP has been described has a 
drug with a favorable glucose-insulin profile (Eastone and Decker, 1997; De Wit et al., 2008) and was 
recently indicated has a protective factor for pre-diabetic HIV-infected patients (Srivanich et al., 2010). 
The NNRTI-based cART has been usually prescribed as the first-line treatment in resource-limited 
settings for several years (Sungkanuparph et al., 2006; Katabira and Oelrichs, 2007; Kiertiburanakul et 
al., 2007; Manosuthi et al., 2007). Moreover, the portuguese guidelines for HIV treatment have 
recently recommend first-generation NNRTI-containning cART as the preferred option for first-line 
therapy (Guerreiro et al., 2012). 
On the other hand, all NNRTI have potential to hepatotoxic reactions (Pereira et al., 2012a) and 
strong evidence suggest that it is upon their biotransformation (Pereira et al., 2012b). Moreover, 
compiling evidence indicates that diabetes might change drug pharmacokinetic (PK) and 
pharmacodinamic (PD) properties (Dostalek et al., 2012). Importantly, PK variations are particular 
concerning for drugs with a narrow therapeutic window, which is the case of antiretrovirals (Kredo et 
al., 2009) for with sub therapeutic concentrations predispose to virological failure and high levels to 
adverse reactions.   
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1.3 Type II diabetes 
 
Type II diabetes (TIIDM) (formerly called non-insulin-dependent or adult-onset) results essentially 
from the interaction of insulin resistance (IR) and insulin secretion deficiency (β-cell dysfunction) 
(Leahy, 2005). IR is defined as a decrease ability of insulin to be sensed by peripheral tissues (liver, 
muscle, fat) to stimulate glucose metabolism and/or inhibit hepatic glucose output. This condition will 
influence the glucose homeostasis (Figure 1.2). Several mechanisms as the serine phosphorylation of 
IRS-1 (Pratipanawatr et al., 2001; Zhande et al., 2002), excess glucosamine (Marshall et al., 1991), 
defective mitochondria (Nyholm et al., 1997; Kelley et al., 2002) or alternate fatty acid effects (Saha 
and Ruderman, 2003; Schrauwen and Hesselink, 2004) have been proposed to explain this 
phenomenon. On the other hand, the impaired insulin secretion is characterized by a defect in the 
glucose-stimulated insulin secretion due dysfunction and/or reduction of a number of pancreatic islet 
β-cell (Kahn, 2000). The reason for this defect is still unknown; however there are many proposed 
pathological processes such as, glucose toxicity (Jonas et al., 1999; Weyer et al., 1999), beta-cell 
exhaustion (Greenwood et al., 1976; Laedtke et al., 2000), impaired pro-insulin biosynthesis (Olson et 
al., 1998) and lipotoxicity (McGarry and Dobbins, 1999; Robertson et al., 2004). 
In addition to TIIDM, the combination of hyperglycemia and hyperinsulinaemia is also associated to 
other metabolic disorders including dyslipidemia, coronary heart disease and lipodystrophy and 
metabolic syndrome. Furthermore, chronic hyperglycemia plays even a significant role in many 
diabetes complications such as macrovascular (e.g. myocardial infarction, stroke) and microvascular 
damage (e.g.  nephropathy, retinopathy, neuropathy) (Engelgau et al., 2004).  
In the patients with pre-diabetes is observed an increase level of glucose in the blood, but these 
levels are not significantly high to be considered as diabetes (< 126 mg/dl). Actually, the pre-diabetic 
individuals present a relative decrease in insulin sensitivity and an increase of insulin secretion by β-
cell with the purpose of compensates the insulin resistance of peripheral tissues (Tabak et al., 2012). 
If the insulin secretion falls, there is a glycemia worsening and TIIDM becomes eventually clinically 
manifest. It is noteworthy, that the prevalence of pre-diabetes is greater than TIIDM in worldwide 
(Gardete Correia et al., 2012; Tabak et al., 2012). 
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Figure 1.2 - Representation of glucose homeostasis. In: (Kahn, 1994) 
This system depends upon a balance between glucose production (liver) and glucose uptake by peripheral 
tissues (fat and muscle, and brain). The hormones glucagon and insulin regulated this equilibrium. Insulin is 
released in order to reduce the glucose level in the blood whereas glucagon promotes hepatic glucose 
production.  
 
 
 
 
1.4 Drug cycle and drug bioactivation 
 
When administered orally, the drug penetrates the epithelial cells in the gastrointestinal tract and 
reaches the liver via hepatic portal vein, before entering in systemic circulation - a process called 
absorption. During the passage for gastrointestinal tract  and the liver, a percentage of the drug may 
be lost due to the presence of enzymes responsible for biotransformation, the presence efflux drug 
transporters and excretion – this is known as first-pass effect (Le, 2012). 
After its absorption, the drug is distributed by the several tissues. The rate and extent of this 
distribution is directly influenced by interactions of the drug with body components, which depend on 
both the physiochemical properties of the drug (e.g. lipid solubility, pK or molecular weight) and 
physiological parameters (e.g. pH, extent of plasma protein binding, blood flow or nature of the tissue) 
(Gibson and Skett, 2001) 
Continuing in the drug cycle, the drug will be excreted mainly via the renal and biliar routes. 
However, in most of the cases, its conversion on polar compounds (more water-soluble), to facilitate 
their excretion, it is necessary. The drugs undergo a number of chemical reactions and this cycle 
phase is known as drug biotransformation or metabolism. For many drugs, this occurs in two phases: 
phase I and phase II reaction. Phase I reactions involve formation of a new or modified functional 
group or cleavage (oxidation, reduction, hydrolysis), while phase II involve conjugation with an 
endogenous substance (e.g. glucuronic acid, sulfate). The metabolites formed in the last phase are 
more polar and thus more readily excreted by the kidneys (in urine) and the liver (in bile). 
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In the phase I reactions, the most important player is the enzymatic system cytochrome (CYP) 
P450, which catalyzes the oxidation of many drugs. These enzymes can be induced or inhibited by 
many drugs or food components, which can consequently enhances the drug toxicity or reduce it 
therapeutic effect. In respect to the phase II phase, glucuronidation, sulfation and glutathione 
conjugation are the most prevalent reactions, which may occur directly on the parent compounds or, 
as normally happens, on the products of phase I (Xu et al., 2005). 
Although, the major intend of biotransformation is to inactivate and detoxify drugs that can harm the 
body, drugs upon biotransformation can also undergo bioactivation chemically reactive electrophilic or 
radical products that are potentially toxic by themselves or that produce oxidative stress (Figure 1.3) 
(Zhou et al., 2005; Walsh and Miwa, 2011).  
The electrophilic intermediates are capable of covalently modifying macromolecules (protein, 
nucleic acids, lipids), giving rise to the formation of drug-macromolecule adducts, which has long been 
associated with drug toxicity (Pumford et al., 1997; Poirier et al., 2000).  
 
 
 
Figure 1.3 - Toxicity related with drug biotransformation. In: (Williams et al., 2012). 
 
 
1.4.1 Drug bioactivation and its implication on its toxicity 
 
The liver is a major target organ for many toxic chemicals/drugs since it is the first site of drug 
metabolism and bioactivation. Moreover, the resulting reactive electrophiles could attack hepatic 
proteins readily because of their proximity (Abboud and Kaplowitz, 2007). The liver has an 
extraordinary ability to regenerate in response to cell damage.  
The chemical-induced liver injury and repair model consist in three stages (Figure 1.4).  
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Upstream events in hepatocytes lead to exposure to electrophilic metabolites, which undergoes 
covalent binding after preferential depletion of glutathione (GSH). Then, upstream events promote 
intracellular stress, production of inflammatory mediators and mild injury which activates the innate 
immune system. Hepatoprotective mediators are secreted to restore cellular and organ structure and 
function and balance of pro- and anti-inflammatory responses, the interplay of which determines 
progression to severe injury or no injury (Chanda and Mehendale, 1995; Liu et al., 2004). 
 
 
Figure 1.4 - A 3-step mechanistic working model of hepatotoxicity: initiation, progression and tissue 
repair (or damage). In (Wang et al., 2007). 
 
 
1.4.2 Diabetes and drug bioactivation 
 
The compensatory liver tissue repair is compromised in diabetes (Sawant et al., 2004; Sawant et 
al., 2006; Wang et al., 2007), as this pathology is associated to a sluggish tissue repair response. The 
high glucose concentration is implicated in inhibition of the hepatocyte proliferation (Caruana et al., 
1986; Chanda and Mehendale, 1995; Rao et al., 1999). Also, the elevated levels of glucose and free 
fatty acid in plasma characteristic of diabetes are associated with an increasing production of free 
radicals and a diminishing of body antioxidant defences (Maritim et al., 2003). In addition, glucose is 
also involved in the production of advanced glycation end-products (AGEs) which inactivate and 
modify enzymes as well as also promote free radical formation. Moreover, it has been proposed that 
AGEs might cause functional alterations in hepatocytes, leading to retarded cell proliferation and 
tissue repair (Cerami et al., 1988; Chanda and Mehendale, 1995). The hyperglycemia impairs the 
antioxidant system, being glutathione (GSH) ,the most abundant low-molecular-weight thiol, one of the 
major and important scavengers of endogenous free radicals and drug electrophic toxic metabolites 
(Dickinson and Forman, 2002).  
Whether diabetes development ends up influencing protein, lipids and carbohydrate metabolism 
and promoting oxidative stress, there is also an effect on the biochemical pathways involved in all drug 
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cycle steps (Table 1.1). While the effects of diabetes mellitus on drug PK and PD properties have 
been well described in experimental animal models; minimal clinical data exists for humans (Dostalek 
et al., 2012).  
The compromised liver repair on diabetes and initial drug bioactivation-based liver damage 
potentiate hepatotoxicity of drugs in diabetes context.  
 
 
Table 1.1 – The effect of TIIDM in drug PK. 
PHARMACOKINETIC 
PRINCIPLES 
EFFECT OF TIIDM REFERENCES 
Absorption 
REDUCED intestinal transit time 
(Jung et al., 2003; Wu et al., 
2004; Triantafyllou et al., 
2007) 
REDUCED gastric mucosal blood flow (Zhu, 1993) 
NO CONSENSUAL gastric emptying time: 
- Decreased 
- Unchanged 
- Increased 
(Keshavarzian et al., 1987; 
Nowak et al., 1995; Lyrenas et 
al., 1997) (Kong et al., 1999) 
(Frank et al., 1995; Schwartz 
et al., 1996) 
Distribution 
REDUCED protein binding capacity (MacKichan, 2006) 
INCREASED free fraction of drugs 
(Ruiz-Cabello and Erill, 1984; 
MacKichan, 2006) 
Biotransformation 
INCREASED enzymatic activity (e.g. CYP 2E1) (Dostalek et al., 2011) 
DECREASED enzymatic activity (e.g. CYP 3A4) 
(Kotlyar and Carson, 1999; 
Brill et al., 2012); (Dostalek et 
al., 2011) 
Excretion INCREASED glomerular filtration rate (Meeme and Kasozi, 2009) 
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1.5 Nevirapine 
 
Nevirapine (NVP) was the first NNRTI approved by the U.S. Food and Drug Administration (FDA) 
in 1996 (FDA, 1996).  This first generation NNRTI is known for its efficacy in prevention of mother-to-
child HIV-transmission, with the drug being commonly indicated for pregnant women and their children 
(Marseille et al., 1999; Ades et al., 2000; Lallemant et al., 2004; AIDS, 2012). Moreover, NVP is 
described by having a favorable lipid and metabolic profile rendering it suitable for use in individuals 
with diabetes, dyslipidemia and other metabolic disorders (Ruiz et al., 2001; Clotet et al., 2003). 
Furthermore, NVP also stands out for being the most used antiretroviral in countries with limited 
resources due to its low cost (Ades et al., 2000). These benefits represent the mean why NVP is 
globally the most prescribed antiretroviral.  
Although the clinical benefits presented, NVP is associated with undesirable adverse effects. 
Among the clinical complications, the most common is skin rash and the most severe is hepatotoxicity. 
These reactions may lead to drug discontinuation or even be fatal (Cattelan et al., 1999; Taiwo, 2006; 
De Lazzari et al., 2008; Medrano et al., 2008). Moreover, NVP can induce hepatocellular neoplasias in 
animal models (Anonymous 2009), and recent epidemiological data suggest an association between 
chronic NNRTI use and an increased incidence of non-AIDS-defining cancers in HIV-1-infected 
patients (Powles et al., 2009).  
The mechanisms underlying NVP toxicity are still not fully understood; however the current 
evidence is strongly consistent with a higher risk in women (Ho et al., 1998; Antinori et al., 2001; 
Bersoff-Matcha et al., 2001) and a subjacent immune mediation (Martin et al., 2005; Taiwo, 2006; 
Yuan et al., 2011; Dong et al., 2012). To allow for sex differences in immune hyper-reactivity, it is 
recommended that in cART-naive women NVP should be initiated only in those with a CD4+ cell count 
< 250 cells/mm3, whereas in men this cut-off is 400 cells/mm3 (Thompson et al., 2010). 
 
The administration of NVP starts with a 200mg dose for the first 14 days and then followed by a 
400 mg daily dose. The lower dose in the first weeks is recommended by therapeutic schedule to 
minimize toxic events. 
 
 
1.5.1 The Pharmacokinetic properties of nevirapine and its toxic reactions 
As a highly lipophilic molecule, NVP is readily absorbed (greater than 90%) after oral 
administration. NVP is about 60% bound to plasma proteins, crosses the placenta and blood–brain 
barrier, and is found in breast milk (Mirochnick et al., 2000). 
The primary route of NVP biotransformation and elimination is represented by the combination of 
CYP P450 metabolism, glucuronide conjugation and urinary excretion (Riska et al., 1999a). In 
humans, NVP biotransformation involves the generation of several hydroxylated phase I metabolites 
(at NVP positions 2, 3, 8 and 12) (Figure 1.5) (Erickson et al., 1999; Riska et al., 1999a). 
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The attempts to correlate NVP exposure and toxicity outcomes have so far been inconclusive (de 
Maat et al., 2003; Regazzi et al., 2003; Almond et al., 2004; Kappelhoff et al., 2005; Hall and 
MacGregor, 2007),which suggests that NVP biotransformation to reactive metabolites, rather than the 
levels of the parent drug, may be the basis of the drug’s adverse effects. Whether or not and how 
these metabolites promote hypersensitivity reactions is unknown, but protein haptenation might be 
involved. In fact, upon bioactivation, these metabolites may generate electrophilic species (Chen et al., 
2008; Srivastava et al., 2010) capable of binding covalently to proteins and other biomacromolecules 
(Figure 1.5) (Chen et al., 2008; Antunes et al., 2009; Wen et al., 2009; Srivastava et al., 2010; Caixas 
et al., 2012; Sharma et al., 2013). The involvement of phase II reactions, and particularly the 
sulphotransferase (SULT)-mediated formation of 12-sulphoxy NVP from 12-hydroxy NVP, has recently 
gained increased support as a major player in this context (Chen et al., 2008; Antunes et al., 2009; 
Wen et al., 2009; Antunes et al., 2010; Meng et al., 2013; Sharma et al., 2013), with protein adducts 
from this pathway having already been detected in patients on therapeutic doses of NVP (Caixas et 
al., 2012; Meng et al., 2013). 
. 
 
Figure 1.5 - NVP biotransformation, disposition and proposed bioactivation pathways. In: (Marinho et al., 
2013). 
NVP (NVP) is metabolized by several isoforms of cytochrome P450 (CYP) yielding several phase I metabolites: 2-
hydroxy NVP (2-OH NVP), 3-hydroxy NVP (3-OH NVP), 8-hydroxy NVP (8-OH NVP), and 12-hydroxy NVP (12-
OH NVP) (Riska et al., 1999a). 12-OH NVP metabolite is further oxidized by CYP450 to yield 4-carboxy-NVP (4-
COOH-NVP) (Chen et al., 2008). The phase I NVP metabolites undergo extensive glucuronidation via UDP-
glucuronosyltransferase (UGT), which represents a major pathway of NVP elimination (Riska et al., 1999a). The 
bioactivation of 12-OH NVP by sulfotransferases (SULTs) can generate 12-sulfoxy NVP, a reactive metabolite 
that binds covalently to proteins and DNA (Antunes et al., 2008; Caixas et al., 2012; Meng et al., 2013). The 
formation of DNA adducts could explain the increased incidence of non-AIDS defining cancers among HIV-
infected patients treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Powles et al., 2009). Also, 
the formation of adducts with proteins could explain the NVP-associated adverse reactions, hepatotoxicity and 
skin rash (Yuan et al., 2011).  The presence of glutathione (GSH) adducts and mercapturates in patients and 
animal models treated with NVP has also been detected (Srivastava et al., 2010). 
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1.6 Rational, aim and work plan 
 
What we know? 
• The number of HIV/infected patients with pre-diabetes is increasing; 
• The NNRTIs efavirenz and nevirapine based cART are recommend first line choice; 
• NVP is a protective factor for pre-diabetes; 
• Diabetes influences drug pharmacokinetics and toxicokinetics; 
• NVP is a drug with a narrow therapeutic window: sub therapeutic NVP concentrations are 
associated with therapeutic failure and resistance development and higher NVP 
concentrations predispose for toxicity; 
• NVP is toxic to the skin and liver and the first steps mechanism underlying it involve 
bioactivation of its phase I metabolite 12-OH NVP and protein adducts formation; 
• Glutathione is a defense system for adducts formation and hepatotoxicity prevention, which 
levels are decreased in diabetes. 
What we need to know? 
• What is the effect of pre-diabetes on NVP pharmacokinetics? 
• What is the effect of pre-diabetes on NVP metabolites profile? 
• What are the effects of NVP on glycemia and insulin sensitivity? 
• What are the effects of NVP in thiols antioxidant system? 
 
Generally, is expected to give new insights on the applicability of NVP in HIV infected patients with 
pre-diabetes, in the view of NVP pharmacokinetic changes induced by diabetes and the consequent 
effect on its efficacy and toxicity.  
 
 
The specific aims of this work are: 
• To evaluate the pre-diabetes effect on: 
- Plasmatic and hepatic NVP bioavailability; 
- NVP biotransformation, phase I metabolites (12-OH NVP and 2-OH NVP) bioavailability 
and metabolite profile. 
 
• To evaluate the NVP effect on: 
- Fasting glycemia, insulin sensitivity and mean arterial pressure; 
- Antioxidant status evaluation via thiol (homocysteine, cysteine, cysteinyl-glycine and 
glutathione) content measurement. 
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2. Materials and Methods
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2.1 Animals maintenance and study group 
 
The animals were females obtained from the vivarium of the NOVA Medical School (FCM), NOVA 
University (UNL), where were kept under temperature and humidity control (21±1 ⁰C; 55±10% 
humidity) with 12/12h light/dark cycles and fed a standard chow (7.4% fat + 75% carbohydrate (4% 
sugar) + 17% protein; SDS diets RM1 (Probiológica, Sintra, Portugal)). 
 All procedures were followed in accordance to the European Union Directive for Protection of 
Vertebrates Used for Experimental and Other Scientific Ends (2010/63/ EU) and were previously 
approved by Ethic Committee for Animal Care and Use at FCM-UNL. 
Five groups of rats aged between 11 to 20 weeks (0.22-0.30 kg) were used: Control group without 
methylcellulose (CC); Control group with methylcellulose (C); Control group treated with NVP solved in 
methylcellulose (C-NVP); Insulin resistant group with methylcellulose (IR); Insulin resistant group 
treated with NVP solved in methylcellulose (IR-NVP). 
NVP (Cipla, Maharashtra, India) was administered at a dose of 40 mg/kg/day in a 0.5% 
methylcellulose solution (MC) in the drinking water bottles, during 8 days. Methylcellulose was used to 
facilitate dissolution of NVP (Mitchell et al., 2003). 
The insulin resistant animal model (IR group) used was the high sucrose (HSu) rat, a lean model of 
combined insulin resistance and hypertension (Ribeiro et al., 2005; Conde et al., 2012), which was 
obtained by submitting the animals to 35% of sucrose GPR Rectapur (VWR, Belgium) in drinking 
water during 28 days (Figure 2.1).  
In IR-NVP group, NVP was administered during 8 days after the 28 days of HSu diet. C and IR 
groups were also administered with the vehicle 0.5% methylcellulose (MC) (Sigma-Aldrich 
Corporation, St. Louis, MO, USA) in drinking water (Figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
CC group 
C group 
C-NVP group 
IR group 
IR-NVP group 
S
ta
n
d
a
rd
 c
h
o
w
 0.5% methylcellulose (8 days) 
 NVP solved in 0.5% methylcellulose (8 days) 
 HSu diet (28 days) + 0.5% methylcellulose (8 days) 
 HSu diet (28 days) + NVP solved in 0.5% methylcellulose (8 days) 
Figure 2.1 - Animal maintenance and study groups. 
CC – Control group without methylcellulose; C – Control group with methylcellulose; C-NVP – Control group 
treated with NVP solved in methylcellulose; IR – Insulin resistant group with methylcellulose; IR-NVP – 
Insulin resistant group with NVP solved in methylcellulose; HSu – High sucrose diet; NVP – Nevirapine.  
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Drinking water daily intake was measured to monitor nevirapine and/or sucrose ingestion, 
depending on group. Animal body weight was assessed twice per week.  
On the last day of the experimental protocol, the rats were fasted overnight and allowed free 
access to water or nevirapine solution, according to the groups.  
After that, the animals were anesthetized with intraperitoneal sodium pentobarbital (60 mg/kg) and 
were transferred to a heating pad to maintain body temperature at 37.5±0.5 ⁰C throughout the 
experiment.  
 
 
2.1.1 Blood sampling and liver collection 
After insulin sensitivity and mean arterial pressure (MAP) measurements (Section 2.3.2.2), blood 
was collected by heart puncture into EDTA pre-coated tubes. The plasma was obtained by blood 
centrifugation (Sigma Laborzentrifugen 2K15, Osterode am Harz, Germany) at 3000 g and 4 ⁰C, for 10 
minutes. The liver was extracted and cryopreserved at -80 ⁰C, until posterior study.  
 
 
2.2 Pharmacokinetic assessment 
 
2.2.1 Drugs and reagents 
The ammonium acetate was obtained from Merck S.A. (Darmstadt, Germany) and acetonitrile from 
Lab-Scan, analytical sciences (Gliwice, Poland). Nevirapine was obtained from Cipla (Maharashtra, 
India) and the 2-OH, 3-OH, 8-OH and 12-OH NVP metabolites were synthesized as previously 
described (Antunes et al., 2010) and used as standards for HPLC quantification. The other reagents 
used were mainly purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). 
 
2.2.2 Preparation of calibration solutions 
Stock solutions of NVP and its phase I metabolites (2-OH, 12-OH, 3-OH and 8-OH NVP) were 
prepared by dissolution in a water:methanol mixture (50:50 v/v). Different standard solutions were 
prepared by solving stock solutions (50 μL) in plasma (950 μL) and liver homogenate in phosphate 
buffered saline (PBS) 1:10 proportion (950 μL) from control rats, to obtain a calibration curve covering 
the concentration range from 0.005 to 10 mg/L. Standard solutions were stored at -80 ⁰C after 
handling. 
 
19 
 
2.2.3 Sample pre-treatment 
A liquid-liquid extraction procedure was performed. Briefly, dichloromethane was added to Wistar 
rat plasma (250 µL) in a proportion of 1:10 and liver homogenate (12 mL) in a proportion of 1:2. The 
organic phase was recovered and the aqueous phase was re-extracted. Two and three extractions 
were performed to plasma and liver, respectively. The total organic phase obtain were collected and 
dried under vacuum (Centrivap micro IR, Labconco (Kansas City, USA)) at 60 ⁰C. The solid residues 
were reconstituted in 150 μL of water:methanol (50:50) mixture, centrifuged (13 000 g, 3 minutes, 
4 ⁰C) for suspension removal and insert into high-performance liquid chromatography (HPLC) vials. 
 
2.2.4 High-performance liquid chromatography (HPLC) analysis 
HPLC analyses of nevirapine and its metabolites was conducted on an Agilent 1100 Series 
system (Agilent Technologies (Santa Clara, CA, USA)) using a reversed-phase Luna C18 (2) column 
(250 mm x 4.6 mm; 5 μm; Phenomenex, Torrance, CA, USA). The mobile phase—10% acetonitrile in 
15 mM ammonium acetate buffer, pH 4—was delivered at a flow rate of 0.8 mL/min for 90 min; the 
flow rate was then increased to 1.5 mL/min over 5 min and maintained at this value for an additional 
period of 19 min. The column temperature was 40 ⁰C, the injection volume was 100 μL and UV 
absorbance was monitored at 254 nm.  
The chromatographic peaks occurred at 34 min for 2-OH NVP, 52 min for 12-OH NVP, 69 min for 
3-OH NVP, 85 min for 8-OH NVP and 109 min for NVP (Figure 2.2). 
The lower limit of quantification of the method was 10 ng/mL for each analyte. 
 
 
Figure 2.2 - Representative chromatogram of a mixture of nevirapine (NVP) and its phase I metabolites 
under the conditions described previously. The analyte concentrations were 2.5ng/mL. 
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2.3 Fasting glycemia, insulin sensitivity and mean arterial pressure 
assessment  
 
2.3.1 Drugs and reagents 
Insulin is commercially available as Humulin Regular® Lilly (Algés, Portugal) in a concentration of 
100 UI/mL.  
 
2.3.2 Measurement of insulin sensitivity 
The insulin tolerance test (ITT) was used to measure insulin sensitivity. The ITT is one of the 
earliest developed methods to assess insulin sensitivity in vivo and provides an estimate of overall 
insulin sensitivity, correlating well with the ‘gold standard’ hyperinsulinaemic–euglycaemic clamp 
(Monzillo and Hamdy, 2003; Conde et al., 2012). This method consists in the administration of an 
intravenous insulin bolus of 0.1 U/kg body weight after an overnight fast, followed by measuring the 
decline in plasma glucose concentration over 15 min at 1 min intervals. The constant rate for glucose 
disappearance (KITT) was calculated using the formula 0.693/t1/2. Glucose half-time (t1/2) was 
calculated from the slope of the least square analysis of plasma glucose concentrations during the 
linear decay phase. Blood samples were collected by tail tipping and glucose levels were measured 
with a glucometer (Abbott Diabetes Care, Amadora, Portugal) and test strips (Abbott Diabetes Care, 
Amadora, Portugal). 
 
2.3.3 Measurement of blood pressure 
To measure mean arterial pressure (MAP), the femoral artery was cannulated under a dissection 
microscope and the catheter was connected to a pressure transducer (model 603; HSE-HA GmgH, 
Harvard Apparatus, Madrid, Spain) and pressure amplifier (Plugsys Housings, modelo 603, HSE-HA 
GmgH, Harvard Apparatus, Madrid, Spain). MAP data were acquired with HSE-Harvard PULMODYN 
W software (Harvard Apparatus, Madrid, Spain). 
 
 
2.4 Antioxidant assessment in rat plasma and liver: the aminothiols.  
 
2.4.1 Reagents 
Sodium hydroxide was purchased from Merck S.A. (Darmstadt, Germany). The ammonium-7-
fluorobenzo-2-oxa-1,3-diazole-4-sulfonic acid (SBD-F) was obtained from Santa Cruz Biotechnology, 
Inc. (Heidelberg, Germany). Stock solutions of cysteine (Cys), homocysteine (HCys), cysteinyl-glycine 
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(Cys-Gly), glutathione (GSH) and N-acetylcysteine (NAC) as well the most of the reagents were 
purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). 
 
2.4.2 Aminothiol measurement in plasma 
The method for sample preparation was adapted from (Nolin et al., 2007). 
2.4.2.1 Standard preparation 
Stock solutions were prepared by solving each thiol in water. These solutions were used to 
prepare standard solutions in PBS in the following concentration range  5 – 800 μM for Cys, 0.625 –
100 μM for HCys, 1.25 – 200 μM for Cys-Gly, and 0.313 – 50 μM for GSH and NAC. 
 
2.4.2.2 Sample preparation 
Samples were prepared following three main steps: thiol reduction, protein precipitation and 
derivatization. In first step, 10 μL of Tris-(2-carboxyethyl)-phosphine hydrochloride (TCEP) 100 g/L 
were added to 100 μL of plasma sample, briefly vortex-mixed and incubated at room temperature for 
30 min. Subsequently, trichloroacetic acid (TCA) 100 g/L with EDTA 1 mM was added, briefly vortex-
mixed and centrifuged at 13000 g, for 10 min, at 4 ⁰C and the supernatant was collected. Afterward, 
the following solutions were added to 50 μL of supernatant: 10 μL of NaOH 1.55 M, 125 μL of borate 
buffer 0.125 M, pH 9.5 with EDTA 4 mM and 50 μL of ammonium-7-fluorobenzo-2-oxa-1,3-diazole-4-
sulfonic acid (SBD-F) 1 g/L in borate buffer 0.125 M with EDTA 4 mM. Samples were briefly vortex-
mixed and incubated for 1 h, at 60 ⁰C, in the dark. Finally, the samples were cooled on ice and 
protected from light until analyses.  
 
2.4.2.3 High-performance liquid chromatography (HPLC) with fluorescence analysis. 
Total of 10 μL of samples were injected onto HPLC. During the analytical runs the samples were 
kept in the refrigerated autosampler at 8 ⁰C.  This quantification was performed in Schimadzu (Kyoto, 
Japan) system, consisting of a LC 9-A solvent delivery pump, a 7725i injector, a RF-10AXL 
fluorescence detector and a CTO-10AS VP column oven. It was used a LiChrospher 100 RP-18 (250 
x 4 mm; 5 μm) column protected by a LiChrospher 100 RP-18e (4x 4 mm; 5 μm) guard-column, both 
from Merck (New Jersey, USA) at 29 ⁰C. The detector was set at excitation and emission wavelengths 
of 385 nm and 515 nm, respectively. Data acquisition and processing were performed on the 
Shimadzu Class VP 7.X software. Isocratic elution method was used with a mobile phases consisted 
of acetate buffer 0.1 M pH 4.5 - methanol 99:1 (v/v) in a flow rate of 0.8 mL/min. Analysis duration was 
20 min. The chromatographic peaks occurred at 6 min for Cys, at 8 min for HCys, at 9 min for Cys-Gly, 
at 13 min for GSH and at 17 min for NAC (Figure 2.3). 
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Figure 2.3 - Representative chromatogram of aminothiols. 
Cys - cysteine, HCys – homocysteine, Cys-Gly - cysteinyl-glycine, GSH – glutathione, NAC - N-acetylcysteine 
(NAC) 
 
 
 
 
2.4.3 Aminothiol measurement in liver 
The method for sample preparation was adapted from (Nolin et al., 2007). 
2.4.3.1 Standard preparation 
Standards of thiols were prepared accordingly the method described for plasma but with different 
concentration ranges: 1.25 – 200 μM for Cys, 0.16 – 25 μM for HCys, 0.31 – 50 μM for Cys-Gly,  5 – 
800 μM for GSH and 0.0781 – 12.5 for NAC. 
 
2.4.3.2 Sample preparation 
For preparation of liver samples an additional step towards thiol extraction, prior to aminothiol 
reduction, was necessary. For that, 250 μL of liver homogenate sample (prepared as described in 
2.2.3 Section) were centrifuged in an Amicon tube of 10 000 MWCO at 3800 g, for 20 min, at 4º C 
before thiol reduction with TCEP 100 g/L. 
 
2.4.3.3 High-performance liquid chromatography (HPLC) with fluorescence analysis. 
The quantification of aminothiols in liver was performed by the same HPLC method conditions 
previously described in 2.4.2.3. Section. 
 
CYS 
[160 M] 
HCYS 
[10 M] 
CYS-GLY 
[40 M] 
GSH 
[10 M] 
NAC 
[10 M] 
23 
 
2.5 Statistical data analysis 
 
The statistical analysis was performed using Graph Prism 5.0 (GraphPad software Inc.). The data 
were presented with mean ± standard error of the mean (SEM). The t-test and Analysis Variance 
(ANOVA) test were used to explore differences among groups. Potential relationships between the 
variables under analysis were explored using Pearson’s and Spearman’s tests. 
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3. Results 
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3.1 Effect of pre-diabetes on nevirapine disposition and biotransformation 
 
The profile of NVP and its phase I metabolites 12-OH and 2-OH NVP, in plasma and liver, for C-
NVP and IR-NVP is represented in Figure 3.1.  
A decline in the plasma concentration of NVP and 12-OH NVP was observed in the IR-NVP group 
(Panel A). The same effect was found in the liver (Panel B). Although, the concentration differences 
for 2-OH NVP were failed to be proved in both liver and plasma. In addition, the profile of metabolites 
has also changed. While 12-OH-NVP is the major metabolite in C-NVP group, this pattern is lost in IR-
NVP animals.  
  
In Figure 3.2 is represented the metabolite ratio NVP/12-OH NVP and NVP/2-OH NVP in C-NVP 
and in IR-NVP. In plasma only the NVP/2-OH NVP ratio was lower and in liver both ratios decreased 
in IR-NVP. 
 
 
 
 
 
3.2 Effect of nevirapine on fasting glycemia, insulin resistance and blood 
pressure in pre-diabetic rats 
 
A control group of animals without treatment and without methylcellulose (CC) was included to 
explore the effects of MC on animals MAP, fasting glycemia and insulin sensitivity and no effects of 
MC were found.   
 
Additionally MAP was similar across groups (Figure 3.3 Panel A). The IR-NVP group is not 
represented because due to a software crash the files were lost.  
The influence of NVP on fasting glycemia and insulin sensitivity is represented in Figure 3.3 Panel 
B and C respectively. In C-NVP, the drug did not modify significantly fasting glycemia. However, when 
NVP was administered after the 28 days of HSu diet, it was able of decrease it.  The ITT constant 
(KITT) was not different across groups.  
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Figure 3.1 - Nevirapine and its phase I metabolites in plasma (A) and liver (B). 
 ( ) Control group treated with NVP (C-NVP) (n = 9 per group); ( ) Insulin resistant group treated with NVP 
(IR-NVP) (n = 6, per group). Comparisons presented reflect differences between groups for the same analyte. 
**P<0.01, ***P<0.005 (One-way ANOVA with Bonferroni’s Multiple Comparison test). NVP – nevirapine; 12-OH 
NVP – 12-hydroxy nevirapine and 2-OH NVP – 2-hydroxy nevirapine. 
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Figure 3.2 - Nevirapine/12-hydroxy nevirapine (NVP/12-OH NVP) and Nevirapine/ 2-hydroxy nevirapine 
(NVP/2 OH NVP) ratios in plasma (A) and liver (B).  
( ) Control group treated with NVP (C-NVP) (n = 9 per group); ( ) Insulin resistant group treated with NVP 
(IR-NVP) (n = 6 per group). Comparisons presented reflect differences between groups for the same analyte. 
*P<0.05, **P<0.01, ***P<0.005 (One-way ANOVA with Bonferroni’s Multiple Comparison test).  
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Figure 3.3 - Effect of NVP intake in mean arterial pressure (A), basal glycemia (B) and insulin sensitivity 
(C).  
( ) Control group (C) (n = 10); ( ) control group treated with NVP (C-NVP) (n = 4); ( ) insulin resistant 
group (IR) (n = 4); ( ) insulin resistant group with NVP (IR-NVP) (n = 6) 
The vertical bars represent mean ± SEM. Comparisons presented reflect differences between IR and IR-NVP 
group: **P<0.01 (One-way ANOVA with Bonferroni multiple comparison test).  
MAP – mean arterial pressure; KITT – constant rate for glucose disappearance. 
31 
 
3.3 Effect of nevirapine on thiol system 
 
The total aminothiol concentration (tHCys, tCys, tCys-Gly and tGSH) found in plasma of each 
group (C, C-NVP, IR, IR-NVP) is represented in Figure 3.4. 
For total homocysteine only insulin resistant effect was considered significant with higher levels in 
IR animals. No effect of treatment was found. There were no differences in total cysteine across 
groups. About tGSH were not found difference too. tCys-Gly plasma levels were higher elevated in 
insulin resistance animals but NVP treatment decreased these levels. 
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Figure 3.4 - Plasma concentrations of Total Aminothiol  
(       ) Not treated (n = 6 per group); (       ) Treated (n = 6 per group). A – total homocysteine level (tHCys); B 
– total cysteine level (tCys); C – total cysteinyl-glycine level (tCys-Gly); D – total glutathione level (tGSH). 
Concentration of aminothiols (mean ± SEM) is expressed in μM. Data are statistically different between 
control and insulin resistant groups (C and IR) ##P<0.01, ###P<0.001(Two-way ANOVA with Bonferroni’s 
Multiple Comparison test). Data are statistically different between not treated and treated groups *P<0.05 
(Two-way ANOVA with Bonferroni’s Multiple Comparison test). 
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For the liver, no significant differences across groups were found to tHCys, tCys and tCys-Gly 
(Figure 3.5 Panel A, B and C). For total glutathione only insulin resistant effect was considered 
significant with higher lower in IR animals (Figure 3.5 Panel D). 
 
Also, tNAC levels were detected on liver (data don’t shown). However it was not detected in all 
animals: four in control (C; C-NVP) and in insulin resistant not treated (IR), and two animals in insulin 
resistant NVP treated group (IR-NVP). While, pre-diabetes seems not have influence on these levels 
the effect of treatment reduced tNAC content (Annex 1). 
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Figure 3.5 - Liver concentrations of Total Aminothiol  
( ) Not treated (n = 6 per group); ( ) Treated (n = 6 per group). A – total homocysteine level (tHCys); B – 
total cysteine level (tCys); C – total cysteinyl-glycine level (tCys-Gly); D – total glutathione level (tGSH). 
Concentration of aminothiols (mean ± SEM) is expressed in μM. Data are statistically different between control 
and insulin resistant groups (C and IR) ###P<0.001(Two-way ANOVA with Bonferroni’s Multiple Comparison test).  
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4. Discussion 
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In the present work an influence of a pre-diabetic status on NVP PK was shown: NVP and its 
phase I metabolites 12-OH NVP and 2-OH NVP presented changes in their disposition and the 
metabolite profile pattern of NVP was changed. Moreover, NVP has no effect on fasting glycemia and 
insulin sensitivity in a non-diabetic context indicating that it can be a good option for pre-diabetes 
prevention, while in a pre-diabetic perspective is associated with a benefic effect on fasting glycemia. 
The drug has no effect on mean arterial pressure and insulin resistance. Moreover, nevirapine is 
associated with a lower degradation of total glutathione. So far, there are no similar studies reported in 
literature, being this data pivotal in this area. 
 
The management of HIV-infection is gradually expanding to include the chronic complications 
associated with this infection and the undesirable effects associated with antiretroviral drugs. For the 
past 20 years, researchers and clinicians have reported changes in fasting glycemia and insulin 
sensitivity in this population. Although, most of the data generated focus on the first available 
antiretroviral as stavudine, didanosine, zidovudine or indinavir (Mulligan et al., 2000; Murata et al., 
2000; Blumer et al., 2008; De Wit et al., 2008) that, due to its toxic profile, have been substituted for 
safer antiretroviral in first-line therapy. Moreover, most of these studies were conducted in advanced 
state diabetic patients, with scarce data on pre-diabetes.   
For the management of HIV patients who develop diabetes, the added responsibilities can be 
overwhelming. The intersection among these two chronic diseases might compromise the treatment 
regimens required for both conditions. Thus, prudent choices for cART must be done for diabetic 
patients or those at higher risks to develop it. 
In fact, antiretroviral represent a very dynamic group in terms of drug innovation, with different 
mechanisms of action and a considerable number of new drugs that became available in the last 20 
years, increasing the possibility of perform a rational and personalized prescription. To give new 
insights on this context, the effects of co-pathologies in a particular antiretroviral pharmacokinetics and 
the consequent effects on its antiretroviral response as well as its toxic effects are worth to pursue.  
A good number of reported data is on PIs class of antiretrovirals (Riddle et al., 2002; Noor et al., 
2004; Schutt et al., 2004). Currently, it is suggested the avoidance of PI-based regiments in patients 
with pre-existing glucose abnormalities as well as the switch the PI to another drug in patients who 
developed diabetes related cART. The use of the old NRTI drugs was also associated to a higher risk 
for diabetes (Gerschenson and Brinkman, 2004; Capeau et al., 2012). In respect to second-generation 
antiretroviral, there is few reported information, once enough time has not been passed yet, to chronic 
effects associated with this drugs to be evaluated. While NVP is available since 1996 and is a first 
generation NNRTI it stands out positively in this scenario. There are not many data on NVP in the 
context of pre-diabetes/diabetes but this antiretroviral has been described in general as a glucose 
friendly drug (Eastone and Decker, 1997; De Wit et al., 2008), and in particular has a protective factor 
for pre-diabetes in HIV-population, by improvement of insulin sensitivity and fasting glycemia (Blanco, 
2004; Srivanich et al., 2010). In fact, the mechanism underlying to this good influence has not yet 
been found.  
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In some HIV-infected patients who developed glucose disorder during treatment, the switch of the 
antiretroviral could implicate a reduction of therapeutic benefits and sometimes the better option 
prescribe an anti-diabetic drug with possibility of a drug-to-drug interactions to occur (Fichtenbaum 
and Gerber, 2002). However, some of the medications used to treat diabetes and the antiretroviral 
medication have similar metabolic pathways. Moreover, antiretroviral agents can influence the activity 
of the CYP P450 system as well as the activity other intervenient on drug metabolism (Xu et al., 2005). 
This is the case of NVP, a well-known CYP3A4 inducer (Pereira, 2012a). This interaction may change 
the efficacy and increase the risk of toxic effects of the both drugs. 
On the other hand, the influence of glucose abnormalities and insulin resistance in pharmacokinetic 
and pharmacodynamic of several drugs has been consistently recognized (Dostalek et al., 2012). 
Although, on the regard of antiretroviral drugs scarce information exists. Antiretroviral are drugs with a 
narrow therapeutic range for each a variation in PK might produce an increased incidence of sub-
therapeutic concentrations and the consequent virologic failure or increased plasma concentrations 
and higher risk of adverse effects (Liu et al., 2010).  
 
 
The choice of the animal model and the related experimental conditions 
In the light of the study of pre-diabetes condition influence on NVP PK, female Wistar rats on a 
sucrose diet were used as study model. Female rats were used due to sex-dependent dimorphic 
profile of the adverse reactions of NVP, with woman being at an increased risk (Ho et al., 1998; 
Bersoff-Matcha et al., 2001). Female sex has been shown to be a risk factor for clinically relevant 
adverse drug reactions (Anderson, 2005; Soldin et al., 2011) and a pharmacokinetic variation has 
been implicated as the main factor underlying the increased rate and wider range of drug-induced 
toxicity reactions in women (Miller, 2001; Anderson, 2008). Regarding NVP, a dissimilar phase I 
metabolite profile was found among men and women: a higher plasma level of the metabolites 12-OH 
and 3-OH NVP in female sex (Marinho et al., 2013). Moreover, females have higher CYP 3A4, 2A6 
and 2B6 activities (Anderson, 2008; Scandlyn et al., 2008). These enzymes are involved in NVP 
phase I biotransformation. About phase II reactions, female mice showed higher hepatic mRNA levels 
of SULT1A1 (isoenzyme involved in the 12-OH NVP bioactivation) compared with male mice (Alnouti 
and Klaassen, 2006; Suzuki et al., 2012). On the other hand, women have lower UDP-
glucuronosyltransferase activity which suggests that may be prone to less efficient detoxification of 
phase I metabolites than men (Anderson, 2008; Gallagher et al., 2010). 
  
 Species differences on drug metabolism are well known (LeCluyse, 2001; Martignoni et al., 2006). 
This turns the choice of the animal model a challenging task. For instance, human liver contains less 
cytochrome P450 per gram than the liver of rat and a faster rate of drug biotransformation and 
elimination in rats (10 a 20 times faster than in man) (Martignoni et al., 2006)). Since it is intended to 
mimic in rat the humans effect, it was necessary a higher dose of the drug, equivalent to human 
therapeutic dose. Regarding NVP, Riska et al. (1999) demonstrated that rat specie is a good 
toxicological, metabolic and pharmacokinetic model for the study of NVP (Riska et al., 1999b). The 
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phase I metabolite profile is similar among rat and man with the proportion of metabolites being similar 
and 12-OH NVP being the major phase I metabolite (Riska et al, 1999b). Adaramoye et al. used 
18 mg/kg body weight NVP dose (equivalent of human therapeutic dose, 400 mg of NVP are taken 
once a day) by oral gavage in a study on the toxicological effect of nevirapine on the liver, kidney and 
testis of male Wistar rat (Adaramoye et al., 2012). As, in other ongoing work of the team, the 
carcinogenic/mutagenic potential (Antunes et al., 2008) of NVP is being explored, to be surely able to 
measure NVP phase I metabolites and as a first pilot study with only 7 days of NVP exposition, a toxic 
dose of NVP 40 mg/kg/day was chose. 
 
As NVP intake is by an oral administration  (Boehringer Ingelheim Pharmaceuticals, 2013) and as 
it was intended to study PK variations, oral administration was selected as the administration route. 
However, the drug administration by gavage might induce stress in animals and since increased 
sympathetic activity is associated with the development and worsen of diabetes (Landsberg, 2006). 
Therefore this way of administration was avoided.  
 
The drug dissolution is one of the main factors to determine its absorption (Mitchell et al., 2003). 
As methylcellulose (MC) enhances drug dissolution properties, NVP was solved in MC 0.5% w/v since 
it is practically insoluble in water (Mitchell et al., 2003; Srivastava et al., 2010). In the preliminary 
experiments, it was found that the volume of drinking water intake per day for each animal was equal 
to the one observed when NVP-MC was included in drinking water. Each rat drank approximately 30 
mL of water per day. Thus, NVP was administered orally in drinking water of the animals.  
 
 In the present work the pre-diabetic model chose was the high sucrose diet (HSu) model. When 
HSu diet is administered for few weeks (more than 4 and less than 9) a lean model of insulin 
resistance and hypertention is obtained (Ribeiro et al., 2005; Conde et al., 2012). Currently, there are 
several animal models of type II diabetes, for example Zucker fa/fa rat which have a spontaneous 
recessive mutation in the fa gene and the fat-fed/streptozotocin (STZ) model (Wang et al., 2007). This 
last model is an obese model of insulin resistance and hypertension and is achieved by submitting the 
animals to a high fat diet. However, although high fat diet induce insulin resistance, is incapable of 
inducing hypoinsulinemia at least until 12 weeks of administration (Reed et al., 2000). Therefore, 
hypoinsulinemia is achieved by submitting the high fat animals to a low dose of STZ, inducing necrosis 
of beta-cells and diminishing diminish the secretion of insulin (Reed et al., 2000). However, obesity is 
not a preponderant characteristic in HIV-population (Amorosa et al., 2005). 
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Is there a change in NVP pharmacokinetics due to pre-diabetes? 
 
The level of NVP was lower in both liver and plasma, suggesting that NVP is being less absorbed 
or highly biotransformated and eliminated. Moreover, the 12-OH NVP levels are lower in both liver and 
plasma, but 2-OH NVP levels do not vary. 
 
Drug absorption is decreased in patients with diabetes (Zhu, 1993; Nowak et al., 1995; Jung et al., 
2003; Wu et al., 2004). A plausible mechanism is an increased first past effect in diabetic condition. 
Little is known about the transporters that influence the disposition of NVP; however it was recently 
discovered a role for the multidrug resistance protein 7 (MRP7) and multidrug resistance type I 
(MDR1) encoded by the adenosine triphosphate-binding cassette gene ABCC10 and ABCB1, 
respectively,  in the efflux transport of NVP (Ciccacci et al, 2010; Liptrott et al., 2012). While the effects 
of diabetes in these transporters are poorly characterized, its activity has not changed in 
hyperglycemic pregnant woman on insulin (Anger et al, 2012). 
 
At first glance it would be said that the lower levels of 12-OH NVP in both liver and plasma were 
expected in pre-diabetes as NVP is being less bioavailable in these animals. However an interesting 
result was observed: the ratios NVP/2-OH and NVP/12-OH were inferior in liver of pre-diabetic rats, 
which revealed a higher biotransformation of NVP into its phase I metabolites. This higher 
biotransformation may explain the low disposition of NVP found in plasma and liver.  Moreover, this 
effect was more pronounced for 2-OH NVP. While, different CYP isoenzymes are involved in 2-OH 
NVP (CYP3A) and 12-OH NVP formation (CYP2A6, 2D, 2C9 and 2C19), its functionality seems not be 
diminished in pre-diabetic animals treated with NVP. Moreover, NVP is a well know CYP inducer 
(Pereira 2012a) and this increased conversion into 12-OH NVP and 2-OH NVP suggests that this 
inductor effect is not lost in diabetes. The effect of diabetes in CYP is dependent on the particular CYP 
isoenzyme, disease status and the model used for the study (Kotlyar and Carson, 1999; Borbas et al., 
2006, Dostalek et al, 2011; Brill et al, 2012). 
 
The pre-diabetic rats showed an increased formation of 2-OH NVP (evaluated by the metabolite 
rate) and higher levels of this metabolite. 
But, surprisingly, pre-diabetic rats showed an increased formation of 12-OH NVP and lower levels 
of this metabolite. As β-glucuronidase appears be increased in diabetes (Perdichizzi et al., 1983), a 
plausible explanation for reduced NVP absorption is that an increased first pass effect due to an 
efficient phase II reactions and drug excretion. Moreover, it might also explain while the 12-OH NVP 
formation is higher, while plasmatic levels are lower. The 2-OH NVP behaved different. Data on UGT 
enzymes involved in the biotransformation of each particular metabolite are scarce to establish the 
comparison. 
Remarkably, is via phase II sulfotransferases (SULT) that 12-OH NVP is bioactivated to 
electrophilic metabolites, which represents the first steps of the mechanism of its hepatotoxicity. 
Moreover, the electrophiles effects are minimized by glutathione which levels are diminished in 
diabetes (Dincer et al., 2002; Sekhar et al., 2011). In order to explore this issue, several experiments 
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as SULT expression experiments, phase II metabolites quantification, markers of hepatotoxicity (liver 
function tests) must be conducted. 
Summing up, besides decreasing NVP absorption, pre-diabetic condition changes the metabolite 
pattern of NVP: the 2-OH NVP was the major metabolite formed instead of 12-OH NVP. This can have 
interesting implications on NVP toxicity, as 12-OH NVP has been described as the main player 
metabolite on NVP-associated toxic events (Caixas et al, 2012, Pereira et al, 2012). Moreover, while 
the lower NVP absorption, also decreases the risk of its toxicity (de Maat et al., 2003; Almond et al., 
2004; Dailly et al., 2004; Kappelhoff et al., 2005; Hall and MacGregor, 2007; Stohr et al., 2008; Wyen 
et al., 2008; Dong et al., 2012; Ratanasuwan et al., 2012) this can have strong implications on drug 
efficacy. NVP is a drug with a narrow therapeutic window and a low genetic barrier (AIDS, 2012) and 
its sub-exposition might lead to resistance development and virological failure with serious therapeutic 
implications in these patients. 
 It is concluded that NVP PK is strongly influenced by HSu diet with plausible diminishing of its 
absorption and a different metabolite profile pattern. The finding of a decreased absorption can have 
significant impact on the NVP dose to be used in IR patients. Moreover on basis of the present data it 
is not possible to describe the fate of 12-OH NVP metabolite and the consequent implications on NVP 
toxicity. Also, further experiments should explore the increased formation of 2-OH NVP.   
 
 
NVP and pre-diabetes: friend or foe? 
Pre-diabetic animals treated with NVP showed no variation in arterial pressure, a benefic decrease 
in fasting glycemia and no influence in insulin sensitivity. Pre-diabetic patients have a proneness to 
present a superior mean blood pressure comparatively with healthy populations (Ryden et al., 2007). 
Also, long term cART use has been associated with an increase risk for heart disease (Dube et al., 
2008; Gopal et al., 2009), but the regiments based on non-nucleoside reverse transcriptase inhibitors 
(NNRTI) seem to be more heart friendly (van Leth et al., 2004b; Parienti et al., 2007; Maggi et al., 
2011). Moreover, several studies reported that NVP raises HDL levels, resulting in an improvement of 
the atherogenic index of patients (van der Valk et al., 2001; van Leth et al., 2004a). The drug has been 
associated to an HDL increase up to 49%, which represents a more pronounced effect than the 
obtained with the currently available HDL-raising drugs and is thought to be due to the stimulation of 
the apolipoprotein A-1 (Apo A-1) production (van Leth et al., 2004a; Sankatsing et al., 2007; Franssen 
et al., 2009). Moreover, it was recently indicated as a protective factor in pre-diabetes (Srivanich et al., 
2010). On this regard NVP might be a good choice for patients with multiple cardiovascular risk factors 
as hypertension, dyslipidemia or diabetes. 
The treatment with NVP improves fasting glycemia in insulin resistant group. This fact is in 
agreement with the clinical studies reporting that NVP might be a protective factor for prediabetes 
(Srivanich et al., 2010). Moreover, Blanco and Shahmanesh observed that subjects treated with NVP 
had significantly lower glucose in plasma than those on protease inhibitor or on the other first 
generation NNRTI-efavirenz (Blanco, 2004; Shahmanesh et al., 2004). The preliminary data, suggest 
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that the lower NVP absorption and the lower availability of 12-OH NVP found in diabetic condition 
might be associated to less liver toxicity and thus improving fasting glycemia. In addition, while no liver 
function tests were performed, a toxic concentration of NVP was administered and even though this 
benefic effect is found.  
According to the previous results about glycemia, would be expected an increase of insulin 
sensitivity (increase KITT), since the lower glucose observed is the result of the normal detection by β-
cells in the pancreas, which leads to the release of insulin. The binding of insulin to the cell membrane 
(muscle, fat or brain cell) sets off a cascade of molecular events that allows glucose uptake. A 
decreased production of glucose instead an increased uptake by liver, could explain the low glucose 
level found and thus the impaired insulin sensitivity. Further studies might be performed to explore the 
mechanisms underlying the improvement of glucose as the pyruvate dehydrogenase kinase-4 activity 
or GLUT4 expression (Jeoung and Harris, 2008). Other variables as a prolonged exposition time to 
NVP, different NVP doses and different IR models are important to explore.  
The majority of the antiretroviral drugs impair glucose homeostasis and insulin resistance (Mulligan 
et al., 2000; Murata et al., 2000;  Justman et al., 2003; Noor et al., 2004;Brown et al., 2005; Tien et al., 
2007; De Wit et al., 2008; Stanley et al., 2009). For instant, different mechanisms have been implied to 
this issue as mitochondrial dysfunction associated to NRTI and inhibition of glucose uptake into 
adipocytes via the GLUT4 glucose transporter for PI. For NVP, almost no information exists. Hong-
Brown et al. observed a decline in phosphorylation of protein 4EBP1 in C2C12 myocytes associated to 
NVP treatment (Hong-Brown et al., 2005). This protein is involved in insulin signaling (Gingras et al., 
1998; Wang et al., 2006). So, this represents a good starting for further studies. 
 
 
Do pre-diabetes predispose to higher NVP toxicity? 
 
The pre-diabetic animals presented lower NVP and lower 12-OH NVP exposition, which raises the 
hypothesis of lower toxicity in this context.  
Recent evidence on the mechanism of NVP toxicity, point towards the bioactivation of the 12-OH 
NVP metabolite into reactive electrophile 12-sulfoxy NVP which has the ability to covalently modify 
proteins and incite the pathway for liver injury progression (Antunes et al., 2010a; Antunes et al., 
2010b; Caixas et al., 2012; Pereira et al., 2012a). This liver injury progression will preferentially occur 
after glutathione depletion. Low glutathione level is characteristic of pre-diabetes (Dincer et al., 2002; 
Sekhar et al., 2011). As so, total aminothiols levels were evaluated in order to explore the effect of 
NVP on endogenous antioxidant defense in pre-diabetes. The non-treated pre-diabetic animals 
presented the great variations in total aminothiols content in plasma and liver. 
Aminothiols are low molecular weight thiol-containing aminoacids that provide numerous roles in 
metabolism and homeostasis, particularly as redox buffers and as components in antioxidant defense 
(Nolin et al., 2007). The impairment of HCys, Cys, GSH and Cys-Gly redox thiol status might be linked 
to the occurrence of several disorders. All these species are interrelated and present a responsibility in 
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redox environment and free radical interactions, by acting as redox buffers (Giustarini et al., 2006). In 
the presence of reactive oxygen species (ROS), they form disulfides in plasma to remove the danger 
compound. Moreover, they also detoxify electrophilic endogenous species as well as the ones formed 
upon drug bioactivation (Antunes et al., 2010a). However, the production of the free radical and the 
electrophilic moieties may exceed the antioxidant capacity of the system (oxidative stress), which 
favors the damage of proteins, lipids and acid nucleic (Dalle-Donne et al., 2006). Oxidative stress is 
considered to be the main factor in the development of diabetic complications and tissue injury 
(Baynes, 1991; Maritim et al., 2003). Non-enzymatic glycation, metabolic stress secondary to the 
changes in energy metabolism and tissue injury resulting from the changes in antioxidant defense 
system are some mechanisms involved in the increase of oxidative stress in diabetes (Baynes, 1991). 
In this work, the total aminothiols were measured which include the free forms (reduced and oxidized) 
and protein-bound forms of all aminothiols. However, the free forms may be more likely to play a role 
in the pathogenesis of diabetes. 
The normal level of total plasma HCys, which includes free HCys, homocystine (HCysSS), and 
mixed disulfides is between 5 and 15 μM (Kaul et al., 2006; Antoniades et al., 2009). The levels of 
tHCys observed are in this range. In diabetes, it is described a higher plasmatic levels of 
homocysteine (de Luis et al., 2005) as it was obtained in the present work. In fact, both hyperglycemia 
and hyperhomocysteinemia lead to a diabetic cardiomyopathy, which is the leading cause of morbidity 
and mortality in this population (Mishra et al., 2010). Across the groups there were no differences of 
HCys in plasma and liver.  
Cys is the aminothiol most abundant in plasma which is in agreement with literature (Dickinson and 
Forman, 2002; Go and Jones, 2011). Interestingly, Cys is the precursor for 3-phophoadenosine 5-
phosphosulfate (PAPS) (Baker, 2006) which serves as the universal sulfonate donor for all 
sulfotransferase reaction (Venkatachalam, 2003). This might suggest that no higher requirement of 
Cys and consequently PAPS is necessary in IR. Along with this hypothesis, IR group might not be at 
increased risk of 12-OH NVP bioactivation. Interestingly, it was recently found a decreased in 
sulfotransferase activity in diabetes (Yalcin et al., 2013). Although, an important safeguard for this data 
interpretation is that scarce information exist on PAPS levels and SULT activities in our model.   
Glutathione is the most important intracellular thiol antioxidant; is crucial for maintaining redox 
homeostasis, protecting cell from oxidative stress. Liver has one of the highest organ contents of GSH 
(Dickinson and Forman, 2002; Go and Jones, 2011). It is reported that the diminished GSH level 
verified in diabetic patients is attributed to limited precursor availability, namely Cys (Sekhar et al., 
2011). So, GSH level depends on Cys disposition and with a dietary supplementation with Cys the 
GSH level can improve and might be a good option to diabetic patients. In the present study, total 
GSH content was negatively influenced by pre-diabetes, although no effect on Cys was observed. 
Moreover, NVP does not influence total GSH and total Cys or any other thiol with the exception of 
Cys-Gly. 
Cys-Gly is an aminothiol that derive for the breakdown of glutathione (Pastore et al., 1998). So, the 
higher is glutathione, the lower is Cys-Gly and vice versa. As Cys-Gly is one of the products of 
extracellular GSH hydrolysis, there is a higher level in plasma than in liver. The higher Cys-Cly level in 
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IR plasma and the lower level in Cys-Gly IR-NVP group are also in agreement that in HSu animals, 
NVP biotransformation suffers a shift towers 2-OH NVP pathway and a decrease in the risk of liver 
injury. 
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5. Conclusion 
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Is NVP a good option for pre-diabetic HIV-infected patients? 
 
The data presented in this study revealed a clear influence of pre-diabetes in NVP 
pharmacokinetic. On the on hand, it seems have a negative influence since the decreased 
bioavailability of NVP in pre-diabetes might suggest an adjustment of NVP dose in pre-diabetic HIV-
infected patients. On the other, it appears be a positive influence since the lower absolute 
concentration of metabolites and the higher phase I biotransformation in pre-diabetic rats suggest an 
increase of glucuronoconjugation which provide the metabolites excretion and eliminates the chance 
of the formation of reactive electrophiles (12-sulfoxy NVP). This hypothesis was also proved by the 
aminothiols results. In pre-diabetic rats was observed a slightly increase of antioxidant defenses after 
NVP treatment. Moreover, the similar level of Cys (crucial for sulfotransferase activity) observed 
among groups suggest that pre-diabetes seems not predispose to a higher 12-sulfoxy formation.  
In respect of NVP role, it might be a good option for HIV-infected patients at higher risk of develop 
pre-diabetic condition since the results revealed an improving of fasting glycemia. 
In this study were observed interesting results which could, in the future, provide a better care to 
HIV-infected patients with pre-diabetes. However, further studies must be conducted in order to 
understand the mechanisms underlying these changes. Also, it would be interesting to do a similar 
study in HIV infected patients with pre-diabetes. In that case, the influence of HIV infection in diabetes 
panorama would be investigated, which was not possible to do in this study.  
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Figure 7.1 - Liver concentrations of tNAC  
( ) Not treated (n = 4 per group); ( ) Treated (n = 4 per Control and n = 2 per IR). 
Concentration of tNAC (mean ± SEM) is expressed in μM. Data are statistically different between 
control and insulin resistant groups (C and IR) #P<0.05 (Two-way ANOVA with Bonferroni’s Multiple 
Comparison test).  
  
